Skip to content

Author

C. Eslinger

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Nov 2026

The role of biomarkers in understanding and targeting adaptive resistance in metastatic colorectal cancer.

Metastatic colorectal cancer (mCRC) is characterized by molecular heterogeneity and the development of adaptive resistance to systemic therapies. Biomarkers have become central to understanding resistance biology and guiding treatment selection, spanning established genomic alterations, circulating tumor DNA (ctDNA)-ba...

C. Eslinger, D. Ahn, Z. Jin et al. · 0 citations
#data science Review Open access Oct 2026

Biweekly gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a systematic review

Pancreatic cancer is associated with high morbidity and mortality. Gemcitabine plus nab-paclitaxel (GA), along with FOLFIRINOX and NALIRIFOX, is a standard first-line treatment for advanced/metastatic pancreatic ductal adenocarcinoma (mPDAC). However, the standard GA schedule (days 1, 8, and 15 of a 28-day cycle)...

C. Hoyek, C. Eslinger, Angelo Pirozzi et al. · 0 citations
Review Sep 2026

Harnessing novel agents to target KRAS-driven pathways in pancreatic cancer

ABSTRACT Introduction Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy in which activating KRAS mutations, present in more than 90% of tumors, constitute the principal oncogenic driver. Advances in structural biology have enabled the pharmacologic targeting of KRAS, a protein historically regarded as...

Joanna Kreidi, C. Hoyek, C. Eslinger et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.